Cyclic derivative of morphiceptin Dmt-cyclo-(D-Lys-Phe-D-Pro-Asp)-NH2(P-317), a mixed agonist of MOP and KOP opioid receptors, exerts anti-inflammatory and anti-tumor activity in colitis and colitis-associated colorectal cancer in mice

This publication has 44 references indexed in Scilit:

• Inhibitory effect of opiates on LPS mediated release of TNF and IL-8
  Acta Oncologica, 2012
• Chronic intestinal inflammation: inflammatory bowel disease and colitis-associated colon cancer
  Frontiers in Immunology, 2012
• Pro‐opiomelanocortin gene delivery suppresses the growth of established Lewis lung carcinoma through a melanocortin‐1 receptor‐independent pathway
  The Journal of Gene Medicine, 2011
• Animal research: Reporting in vivo experiments: The ARRIVE guidelines
  British Journal of Pharmacology, 2010
• Inflammatory bowel disease and intestinal cancer: a paradigm of the Yin–Yang interplay between inflammation and cancer
  Oncogene, 2010
• COX-2 inhibitor celecoxib prevents chronic morphine-induced promotion of angiogenesis, tumour growth, metastasis and mortality, without compromising analgesia
  British Journal of Cancer, 2007
• Functional Expression of μ-Opioid Receptors in the Human Colon Cancer Cell Line, HT-29, and their Localization in Human Colon
  Digestive Diseases and Sciences, 2007
• Muc2-Deficient Mice Spontaneously Develop Colitis, Indicating That MUC2 Is Critical for Colonic Protection
  Gastroenterology, 2006
• Mu opioid receptor expression is increased in inflammatory bowel diseases: implications for homeostatic intestinal inflammation
  Gut, 2005
• The involvement of nitric oxide in the enhanced expression of μ‐opioid receptors during intestinal inflammation in mice
  British Journal of Pharmacology, 2005